Trials / Terminated
TerminatedNCT00105170
Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors
A Phase I, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of hCBE-11, a Humanized Monoclonal Antibody, in Subjects With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I, open-label, dose-escalation study on subjects with advanced solid tumors. This is the first study of hCBE-11 in humans and is designed to determine the safety and how well patients tolerate this investigational drug. The study duration is two years with treatment visits occurring weekly for either 4 or 8 weeks, follow-up for 8 weeks and long-term follow-up contact every 3 months thereafter.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | hCBE-11 |
Timeline
- Start date
- 2005-01-01
- Primary completion
- 2006-08-01
- Completion
- 2006-08-01
- First posted
- 2005-03-09
- Last updated
- 2013-04-26
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00105170. Inclusion in this directory is not an endorsement.